Colorectal and other GI cancers:
Indications for QINLOCK:
Treatment of adults with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Swallow whole. 150mg once daily until disease progression or unacceptable toxicity. Dose modifications: see full labeling.
Risk of new primary cutaneous malignancies. Perform skin exams prior to initiation and during therapy. Manage suspicious skin lesions with excision and dermatopathologic evaluation. Uncontrolled hypertension: do not initiate. Control BP prior to initiation; monitor and treat during therapy as appropriate. Cardiac dysfunction. Assess ejection fraction by echocardiogram or MUGA scan prior to initiation, during therapy, and as clinically indicated. Permanently discontinue if Grade 3/4 left ventricular systolic dysfunction occurs. Impaired wound healing: withhold for ≥1 week prior to elective surgery; do not give for ≥2 weeks after major surgery and until adequate healing. Safety of resuming therapy after resolution of wound healing complications has not been established. Moderate or severe hepatic impairment. Severe renal impairment. Embryo-fetal toxicity. Advise females of reproductive potential and males (w. female partners) to use effective contraception during and for ≥1 week after the last dose. Pregnancy: exclude status prior to initiation. Nursing mothers: not recommended (during and for ≥1 week after the last dose).
Tyrosine kinase inhibitor.
Potentiated by strong CYP3A4 inhibitors; monitor frequently. May be antagonized by strong CYP3A4 inducers; avoid.
Alopecia, fatigue, nausea, abdominal pain, constipation, myalgia, diarrhea, decreased appetite, palmar-plantar erythrodysesthesia, vomiting; lab abnormalities (eg, increased lipase, decreased phosphate).